- Home
- AIMD vs ALLR Comparison
AIMD vs ALLR Comparison
Compare AIMD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- ALLR
- Stock Information
- Founded
- AIMD 1984
- ALLR 2004
- Country
- AIMD United States
- ALLR United States
- Employees
- AIMD N/A
- ALLR N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- ALLR Health Care
- Exchange
- AIMD Nasdaq
- ALLR Nasdaq
- Market Cap
- AIMD 16.9M
- ALLR 15.8M
- IPO Year
- AIMD N/A
- ALLR N/A
- Fundamental
- Price
- AIMD $3.43
- ALLR $1.47
- Analyst Decision
- AIMD
- ALLR Strong Buy
- Analyst Count
- AIMD 0
- ALLR 1
- Target Price
- AIMD N/A
- ALLR $9.00
- AVG Volume (30 Days)
- AIMD 88.9K
- ALLR 21.6M
- Earning Date
- AIMD 11-05-2025
- ALLR 11-13-2025
- Dividend Yield
- AIMD N/A
- ALLR N/A
- EPS Growth
- AIMD N/A
- ALLR N/A
- EPS
- AIMD N/A
- ALLR N/A
- Revenue
- AIMD $110,870.00
- ALLR N/A
- Revenue This Year
- AIMD N/A
- ALLR N/A
- Revenue Next Year
- AIMD N/A
- ALLR N/A
- P/E Ratio
- AIMD N/A
- ALLR N/A
- Revenue Growth
- AIMD 70.25
- ALLR N/A
- 52 Week Low
- AIMD $2.00
- ALLR $0.61
- 52 Week High
- AIMD $5.00
- ALLR $3.71
- Technical
- Relative Strength Index (RSI)
- AIMD 49.24
- ALLR 50.25
- Support Level
- AIMD $3.30
- ALLR $1.43
- Resistance Level
- AIMD $3.61
- ALLR $1.92
- Average True Range (ATR)
- AIMD 0.26
- ALLR 0.19
- MACD
- AIMD -0.06
- ALLR -0.04
- Stochastic Oscillator
- AIMD 18.29
- ALLR 6.35
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.